https://www.businesswire.com/news/home/20191216005622/en/

GUILFORD, Conn.--(BUSINESS WIRE)--Dec 16, 2019--

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to complete a bridge financing transaction (the “Bridge Financing”) for gross proceeds of approximately USD$500,000.